When did INSIGHT MOLECULAR DIAGNOSTIC (IMDX) report earnings last quarter?
INSIGHT MOLECULAR DIAGNOSTIC (IMDX) last reported earnings on 3/26/2026.
INSIGHT MOLECULAR DIAGNOSTIC (IMDX) Earnings History & Surprises
NASDAQ:IMDX • US68235C2061
Current stock price
3.76 USD
+0.32 (+9.3%)
At close:
3.77 USD
+0.01 (+0.27%)
After Hours:
IMDX Earnings overview
Past quarterly earnings results for INSIGHT MOLECULAR DIAGNOSTIC (IMDX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.27
- Revenue Estimate
- 289.68K
Last Reported
Most Recent- Release Date
- Mar 26, 2026
- Period
- Q4 / 2025
- EPS Reported
- -$0.72
- EPS Surprise
- -197.53%
- Revenue Surprise
- 285.06%
Beat Rate
Last 8 Quarters 31%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.72 | -0.24 | -197.53% | 62.69% | 1.139M | 295.8K | 285.06% | -23.35% |
| Q3 2025 | -0.34 | -0.21 | -58.92% | 65.31% | 260K | 289.68K | -10.25% | 126.09% |
| Q2 2025 | -0.30 | -0.23 | -27.88% | 16.67% | 518K | 297.84K | 73.92% | 398.08% |
| Q1 2025 | -0.26 | -0.24 | -7.78% | 76.99% | 2.138M | 129.285K | 1,553.71% | 1,114.77% |
| Q4 2024 | -1.93 | -0.44 | -342.79% | 8.96% | 1.486M | 102K | 1,356.86% | 373.25% |
| Q3 2024 | -0.98 | -0.44 | -120.36% | -20.99% | 115K | 204K | -43.63% | -73.26% |
| Q2 2024 | -0.36 | -0.57 | 36.86% | 66.36% | 104K | 324.87K | -67.99% | -77.39% |
| Q1 2024 | -1.13 | -0.68 | -65.76% | -382.50% | 176K | 357K | -50.70% | -41.33% |
| Q4 2023 | -2.12 | -1.16 | -82.80% | 73.50% | 314K | 323.003K | -2.79% | 16.30% |
| Q3 2023 | -0.81 | -1.03 | 21.18% | 49.38% | 430K | 318.75K | 34.90% | 514.29% |
| Q2 2023 | -1.07 | -1.33 | 19.31% | 23.57% | 460K | 369.75K | 24.41% | 91.67% |
| Q1 2023 | 0.40 | -1.88 | 121.31% | 118.18% | 300K | 353.328K | -15.09% | -21.05% |
| Q4 2022 | -8.00 | -1.92 | -316.30% | -233.33% | 270K | 1.453M | -81.42% | 113.92% |
| Q3 2022 | -1.60 | -2.30 | 30.49% | 46.67% | 70K | 1.514M | -95.38% | -92.86% |
| Q2 2022 | -1.40 | -2.43 | 42.49% | 41.67% | 240K | 2.752M | -91.28% | -88.18% |
| Q1 2022 | -2.20 | -2.45 | 10.13% | -120.00% | 380K | 2.282M | -83.35% | -66.07% |
| Q4 2021 | -2.40 | -2.59 | 7.47% | -33.33% | -1.94M | 3.704M | -152.38% | -488.00% |
| Q3 2021 | -3.00 | -2.37 | -26.77% | -50.00% | 980K | 1.795M | -45.40% | 75.00% |
| Q2 2021 | -2.40 | -2.04 | -17.65% | 14.29% | 2.03M | 1.598M | 27.03% | 1,350.00% |
| Q1 2021 | -1.00 | -2.04 | 50.98% | 61.54% | 1.12M | 849.997K | 31.77% | 5,500.00% |
| Q4 2020 | -1.80 | -2.24 | 19.79% | - | 500K | 839.797K | -40.46% | - |
| Q3 2020 | -2.00 | -1.94 | -3.20% | - | 560K | 378.593K | 47.92% | - |
| Q2 2020 | -2.80 | -2.12 | -31.98% | - | 140K | 48.144K | 190.79% | - |
| Q1 2020 | -2.60 | -2.16 | -20.24% | - | 20K | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
0
Average EPS beat (4)
-73.03%
Max EPS beat (4)
-7.78%
Min EPS beat (4)
-197.53%
Revenue beat statistics
Revenue beat (4)
3
Average Revenue beat (4)
475.61%
Max Revenue beat (4)
1,553.71%
Min Revenue beat (4)
-10.25%
Analysis
In the last 4 quarters, IMDX has not beaten EPS estimates in any release
IMDX has beaten revenue estimates in 3 out of the last 4 releases
In the last 4 quarters, IMDX reported -73.0% below the EPS estimates on average.
In the last 4 quarters, IMDX has beaten the revenue estimates by 475.6% on average.
Related analysis
INSIGHT MOLECULAR DIAGNOSTIC / IMDX Earnings FAQ
Did IMDX stock beat earnings estimates in the most recent quarter?
INSIGHT MOLECULAR DIAGNOSTIC (IMDX) missed EPS estimates and beat revenue estimates in the most recent quarter.
Can you provide information on how often INSIGHT MOLECULAR DIAGNOSTIC beats earnings estimates?
In the last 4 quarters, INSIGHT MOLECULAR DIAGNOSTIC (IMDX) has beaten EPS estimates in 0 out of 4 releases.